{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-116808","form_type":"8-K","ticker":"IPSC","cik":"0001850119","company_name":"Century Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.735680+00:00","generated_at":"2026-06-21T23:54:35.831992+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Century Therapeutics Q3 net loss $30.7M; cash $395.3M; CNTY-101 trial imminent","bullets":["Net loss $30.7M for Q3 2022 vs $26.0M in Q3 2021; R&D expenses rose to $25.9M.","Cash, cash equivalents, and investments totaled $395.3M at Sep 30, 2022; runway into 2025.","Full-year 2022 GAAP operating expense guidance lowered to $140M-$145M (incl. $10-$15M stock comp).","Phase 1 ELiPSE-1 trial of CNTY-101 in B-cell malignancies to begin imminently after FDA clearance.","Appointed Daphne Quimi and Timothy Walbert to Board; SITC data and R&D Day on Nov 11."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-116808","json":"https://secwatch.observer/filing/0001104659-22-116808.json","markdown":"https://secwatch.observer/filing/0001104659-22-116808.md","text":"https://secwatch.observer/filing/0001104659-22-116808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850119/000110465922116808/0001104659-22-116808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850119/000110465922116808/tm2230058d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:54:35.831992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89bf80d68909c287ddd48818624c7ff436436e72","claim":"Century Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue Collaboration revenue was $2.2 million, net income Net loss was $30.7 million. Guidance lowered.","evidence_excerpt":"of $118.5 million) compared to net cash used in operations of $64.7 million for the nine months ended September 30, 2021. ● Collaboration Revenue: Collaboration revenue was $2.2 million for the three months ended September 30, 2022, generated through the Company’s collaboration, option and license agreement with BMS. ● Research and Development (R&D) expenses","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850119/000110465922116808/0001104659-22-116808-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"Collaboration revenue was $2.2 million"},{"label":"Net income","value":"Net loss was $30.7 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}